MedTrace Logo

Busulfan and Melphalan Conditioning in Multiple Myeloma

NCT01923935 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2013-08-19

No results posted yet for this study

Summary

The purpose of this study is to determine whether intravenous busulfan and melphalan as a conditioning regimen is effective in the treatment of multiple myeloma undergoing autologous stem cell transplantation.

Conditions

Interventions

DRUG

BUSULFEX®

BUSULFEX® 3.2 mg/kg/day iv once daily over 3 hours (day-6\~day-4)

DRUG

Alkeran®

Alkeran® 70 mg/m2/day iv once daily over 30 minutes (day-3\~day-2)

Sponsors & Collaborators

  • Korea Otsuka Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Chonnam National University Hospital

    lead OTHER

Principal Investigators

  • Je-Jung Lee, M.D., Ph.D. · Chonnam National University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2014-01-31
Completion
2015-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01923935 on ClinicalTrials.gov